Gilead Sciences Inc GIS
News
Gilead, Genesis Therapeutics to Use AI to Discover Novel Therapies
Gilead Sciences Currently Up Nine Consecutive Days, on Pace for Longest Winning Streak Since July 2023 — Data Talk
Gilead Sciences Currently Up Eight Consecutive Days, on Pace for Longest Winning Streak Since July 2023 — Data Talk
Gilead Sciences Receives Accelerated Approval from FDA
Gilead Sciences posts higher Q2 profit and revenue on increased sales
Gilead Sciences Posts Higher 2Q Profit, Revenue on Increased Sales
Gilead Sciences Chief Medical Officer to Step Down
Pfizer signals progress on obesity pill, boosting stock
Gilead Sciences on Track for Highest Close Since April — Data Talk
Gilead Sciences Up Over 7%, On Pace for Largest Percent Increase Since October 2022 — Data Talk Update
Gilead Sciences On Track for Largest Percent Increase Since August 2023 — Data Talk
Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial
Gilead's HIV prevention treatment found 100% effective in late-stage trial
Gilead's quarterly loss is narrower than expected
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration
Xilio Shares Take Flight Premarket After Gilead Deal
Gilead Says FDA Expands Approval of Chronic Hep-B Infection Treatment for Use in Kids
Xilio Therapeutics Plans Private Placement, Job Cuts